written on 21.04.2017

PharmaBoardroom Releases Healthcare & Life Sciences Review Greece


PharmaBoardroom today releases its new 42-page Healthcare & Life Sciences Review Greece 2017.

This report offers companies, investors, policymakers, and stakeholders crucial insight into Greece; a country with an admirable and long-standing history in healthcare and pharmaceuticals, but one that is still struggling to find its way out of a national debt crisis. The interviewees from government, associations, MNCs and local players featured in the report discuss the various issues and barriers to growth created by economic austerity policies, but also how innovative and quick-thinking players have found opportunity in crisis and are adapting to the new reality.

The report features in-depth exclusive interviews with leading figures from public institutions and private companies, comprehensive articles, and up-to-date facts and figures on Greece’s macroeconomic situation, as well as its healthcare and pharma sectors.


Featured topics include:


Market Access

Generics Penetration

Cuts and Clawbacks

Clinical Trials

Pharma Logistics


The report features in-depth interviews with:

Bersimis Sotirios, EOPYY

Mihalis Himonas, SFEE

Theodore Tryfon, PEF

Vassilios Katsos, Pharmathen

Sophia ROmboli & Konstantinos Karakostas, ZeinCRO

John Kandylis, Olympias Logistics

John Bouros, Alvion

Evi Christofilopoulou, MP for Labour, Social Insurance and Health


“It is important to recognize the extent to which the Greek market has been disfigured by the country’s financial and banking woes. Prior to the crisis, Greek pharma could legitimately claim to be the sixth largest market in Europe”

Christos Dakas, Shire

“The government’s commitment to capping the public pharma budget to one percent of GDP is absolutely nonsensical… that particular metric only works when a country’s GDP is at its peak and stable, and enjoys the potential for growth”

Harry Nardis, Astellas

“In every civilized country, the trend has been for healthcare and pharmaceutical expenditure to increase every year as costlier, new generation sophisticated products enter the market. This regressive trend is thus clearly unsustainable.”

Philippe Lambrinos, Pierre Fabre

“Regardless of the challenges posed by the financial squeeze, most actors are perceptive of the underlying potential of this important market and acknowledge that there are no shortages of patients with inelastic needs that need responding to”

Konstantinos Kofinas, Merck 

Click here to register and download the report.